Last reviewed · How we verify

Botulinum toxin type A injection

Hugel · FDA-approved active Small molecule ✓ Verified May 2026

Botulinum toxin type A injection is a Neurotoxin; botulinum toxin preparation Small molecule drug developed by Hugel. It is currently FDA-approved for Cervical dystonia, Blepharospasm, Hemifacial spasm. Also known as: Botulax®, Botox® 100 U, Allergan Pharmaceuticals Westport, Ireland, Botox, onabotulinumtoxinA.

Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

Botulinum toxin type A injections are used to treat various conditions, including cutaneous leiomyomas, high tone pelvic floor dysfunction, facial corrections, and facial lines. The injections are administered with or without EMG guidance to help manage these conditions.

At a glance

Generic nameBotulinum toxin type A injection
Also known asBotulax®, Botox® 100 U, Allergan Pharmaceuticals Westport, Ireland, Botox, onabotulinumtoxinA, BOTOX®
SponsorHugel
Drug classNeurotoxin; botulinum toxin preparation
TargetSNAP-25 (synaptosome-associated protein of 25 kDa)
ModalitySmall molecule
Therapeutic areaNeurology; Aesthetics; Dermatology
PhaseFDA-approved

Mechanism of action

The toxin irreversibly cleaves SNAP-25, a protein essential for acetylcholine vesicle fusion and release at motor nerve terminals. This prevents muscle contraction in the injected area, producing a temporary paralytic effect that lasts 3–4 months. The effect is reversible as the body gradually regenerates new nerve terminals and SNARE proteins.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Botulinum toxin type A injection

What is Botulinum toxin type A injection?

Botulinum toxin type A injection is a Neurotoxin; botulinum toxin preparation drug developed by Hugel, indicated for Cervical dystonia, Blepharospasm, Hemifacial spasm.

How does Botulinum toxin type A injection work?

Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

What is Botulinum toxin type A injection used for?

Botulinum toxin type A injection is indicated for Cervical dystonia, Blepharospasm, Hemifacial spasm, Glabellar lines (aesthetic), Crow's feet (aesthetic).

Who makes Botulinum toxin type A injection?

Botulinum toxin type A injection is developed and marketed by Hugel (see full Hugel pipeline at /company/hugel).

Is Botulinum toxin type A injection also known as anything else?

Botulinum toxin type A injection is also known as Botulax®, Botox® 100 U, Allergan Pharmaceuticals Westport, Ireland, Botox, onabotulinumtoxinA, BOTOX®.

What drug class is Botulinum toxin type A injection in?

Botulinum toxin type A injection belongs to the Neurotoxin; botulinum toxin preparation class. See all Neurotoxin; botulinum toxin preparation drugs at /class/neurotoxin-botulinum-toxin-preparation.

What development phase is Botulinum toxin type A injection in?

Botulinum toxin type A injection is FDA-approved (marketed).

What are the side effects of Botulinum toxin type A injection?

Common side effects of Botulinum toxin type A injection include Injection site pain or bruising, Headache, Eyelid ptosis, Muscle weakness, Neck pain, Flu-like symptoms.

What does Botulinum toxin type A injection target?

Botulinum toxin type A injection targets SNAP-25 (synaptosome-associated protein of 25 kDa) and is a Neurotoxin; botulinum toxin preparation.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing